Elicio Therapeutics Income Statement (2020-2026) | ELTX

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.54M1.46M25.14M1.65M0.65M
Cost of Revenue (Quarter)
0.43M
Gross Profit (Quarter)
0.54M1.46M24.70M
Operating items
Research & Development (Quarter)
14.44M13.29M6.67M11.67M5.04M4.59M4.29M5.48M4.94M7.26M6.16M7.56M8.18M7.21M10.71M7.78M7.01M5.04M5.08M6.76M
Selling, General & Administrative (Quarter)
4.34M3.93M4.21M4.47M1.19M1.18M1.67M2.32M2.83M3.51M3.23M2.68M2.74M3.14M2.77M2.96M3.08M3.01M3.76M3.85M
Restructuring Costs (Quarter)
2.80M3.15M
Other Operating Expenses (Quarter)
0.43M-2.80M-3.15M-0.10M0.10M0.00M
Operating Expenses (Quarter)
18.78M17.22M11.31M16.13M6.23M5.77M5.96M7.80M7.78M10.77M9.39M10.24M10.92M10.34M13.48M10.74M10.09M8.04M8.84M10.60M
Operating Income (Quarter)
-18.24M-15.76M14.63M-14.48M-6.23M-5.77M-5.96M-7.80M-7.78M-10.77M-9.39M-10.24M-10.92M-10.34M-13.48M-10.74M-10.09M-8.04M-8.84M-10.60M
EBIT (Quarter)
-18.24M-15.76M14.63M-14.48M-6.23M-5.77M-5.96M-7.80M-7.78M-10.77M-9.39M-10.24M-10.92M-10.34M-13.48M-10.74M-10.09M-8.04M-8.84M-10.60M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.06M0.01M0.04M0.25M0.07M0.15M0.14M0.18M0.21M0.17M0.20M0.16M
Other Non Operating Income (Quarter)
-0.02M-0.20M-7.19M0.11M-0.11M-0.94M0.11M0.49M-0.03M0.15M-0.01M-0.00M0.01M0.01M
Non Operating Income (Quarter)
1.17M0.05M0.26M0.24M-1.07M-1.43M-0.69M-0.22M0.22M0.11M0.44M-1.59M3.69M-8.49M-0.53M-0.47M-0.47M-2.04M1.12M-1.22M
Net income details
EBT (Quarter)
-18.24M-15.76M14.63M-14.48M-7.30M-6.84M-6.00M-8.14M-8.45M-10.53M-9.32M-10.13M-10.84M-10.30M-13.71M-10.70M-10.12M-8.27M-9.18M-10.85M
Profit After Tax (Quarter)
-17.07M-15.70M14.89M-7.06M-7.30M-7.20M-6.65M-8.03M-7.56M-10.66M-8.95M-11.83M-7.23M-18.84M-14.00M-11.21M-10.56M-10.08M-7.72M-11.82M
Equity Income (Quarter)
-0.02M0.03M-0.17M0.01M0.13M0.01M
Income from Continuing Operations (Quarter)
-18.24M-15.76M14.63M-14.48M-7.30M-6.84M-6.00M-8.14M-8.45M-10.53M-9.32M-10.13M-10.84M-10.30M-13.71M-10.70M-10.12M-8.27M-9.18M-10.85M
Consolidated Net Income (Quarter)
-18.24M-15.76M14.63M-14.48M-7.30M-6.84M-6.00M-8.14M-8.45M-10.53M-9.32M-10.13M-10.84M-10.30M-13.71M-10.70M-10.12M-8.27M-9.18M-10.85M
Income towards Parent Company (Quarter)
-18.24M-15.76M14.63M-14.48M-7.30M-6.84M-6.00M-8.14M-8.45M-10.53M-9.32M-10.13M-10.84M-10.30M-13.71M-10.70M-10.12M-8.27M-9.18M-10.85M
Net Income towards Common Stockholders (Quarter)
-18.24M-15.76M14.63M-14.48M-7.30M-6.84M-6.00M-8.14M-8.45M-10.53M-9.32M-10.13M-10.84M-10.30M-13.71M-10.70M-10.12M-8.27M-9.18M-10.85M
Additional items
EPS (Basic) (Quarter)
-0.58-0.530.58-0.48-23.20-22.67-20.75-24.77-2.61-1.27-0.21-1.15-0.64-1.39-1.02-0.87-0.66-0.60-0.49-0.65
EPS (Weighted Average and Diluted) (Quarter)
-0.58-0.530.58-0.48-23.20-22.67-20.75-24.77-2.61-1.27-0.21-1.15-0.64-1.39-1.02-0.87-0.66-0.60-0.49-0.65
Shares Outstanding (Weighted Average) (Quarter)
29.67M27.67M28.24M29.96M0.31M0.32M0.32M0.32M2.89M3.89M5.06M10.27M10.78M13.58M12.20M12.95M16.06M15.25M15.31M18.21M
Shares Outstanding (Diluted Average) (Quarter)
29.67M29.83M28.24M29.96M0.31M0.31M0.32M0.32M1.62M8.38M5.06M10.27M11.28M13.58M12.20M12.95M16.06M16.69M15.31M18.21M
EBITDA (Quarter)
-17.00M-15.56M14.86M-14.34M-7.30M-7.20M-6.65M-8.03M-7.56M-10.68M-9.12M-11.90M-7.20M-18.80M-13.98M-11.18M-10.49M-10.04M-7.81M-11.82M
Interest Expenses (Quarter)
1.07M1.08M0.09M0.34M0.71M0.00M0.00M0.04M0.05M0.14M0.23M0.18M0.19M0.43M0.34M0.41M